Therefore, combination of BYL719 and EGFR-TKIs may be a potential effective and safe strategy for EGFR mutant NSCLC patients with PI3K pathway aberrations, and warrant further clinical studies. This evidence concerns the gene EGFR and non-small cell lung carcinoma.